Cantor Fitzgerald's Brett Knoblauch on how Stargate could be a bullish opportunity for crypto miners
Brett Knoblauch, Cantor Fitzgerald head of digital asset research, joins 'Power Lunch' to discuss the energy needed to power ...
Trump’s Pick for Commerce Secretary Reveals Positions at More Than 800 Companies
Howard Lutnick, the wealthy Wall Street executive whom President Trump has tapped to lead the Department of Commerce, ...
Mansion Global5d
Widow of Cantor Fitzgerald Founder Relists $43 Million Manhattan Townhouse
The 20-foot wide mansion was built in 1869 along with three others on East 74th Street, and was significantly redesigned in ...
Redwire assumed with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Colin Canfield raised the firm’s price target on Redwire (RDW) to $28 from $6 and keeps an Overweight rating on the ...
Cantor’s Lutnick Settles Suit Over $50 Million Newmark Bonus
Cantor Fitzgerald LP Chief Executive Officer Howard Lutnick settled a lawsuit over his $50 million bonus tied to Newmark Group Inc. days before he is set to appear in front of the US Senate for a ...
FY2024 EPS Estimates for Exagen Reduced by Cantor Fitzgerald
Research analysts at Cantor Fitzgerald lowered their FY2024 earnings estimates for Exagen in a research report issued to ...
Vertex Pharmaceuticals (VRTX) Receives a Buy from Cantor Fitzgerald
Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...
US Senate committee to hold Jan. 29 hearing on Trump commerce nominee
The Senate Commerce Committee said on Wednesday it would hold a Jan. 29 hearing on President Donald Trump's nominee to lead ...
Morningstar1mon
Cantor Fitzgerald Equity Opp A
Cantor Fitzgerald Equity Opportunity Fd earns a Low Process Pillar rating. The primary detractor from the rating is the fund's unimpressive long-term risk-adjusted performance. This can be seen in ...
Cantor Fitzgerald Comments on ZVRA FY2025 Earnings
Analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Zevra Therapeutics in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen ...